Protective Effect of N-acetylcysteine Against From Ototoxicity

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (CAPD). Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis despite their potential risk for ototoxicity. NAC is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress. The aim of this study was to examine whether ototoxicity due to antibiotics used in the treatment of CAPD peritonitis can be prevented by N-acetylcysteine

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TC Erciyes University
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• End-stage renal disease

• Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy

• Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode

Exclusion Criteria:

• Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months

• Detection of mechanical occlusion of external ear

• Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry

• History of a continuous ambulatory peritoneal dialysis related peritonitis